National Institute for Health and Care Excellence

CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack

People who have had a stroke are at increased risk of further occlusive vascular events, such as recurrent stroke or myocardial infarction. For people who have had a non‑cardioembolic ischaemic stroke ...
London South East

Results presented re. NHS CYP2C19 Genotype Testing

Pilot Programme Study Results underpinning NHS Implementation Guide for CYP2C19 Genotype Testing Presented at the UK Stroke Forum genedrive plc (AIM: GDR), the point of care pharmacogenetic testing ...
London South East

NHS implementation guide published for CYP2C19

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, notes the publication of the "NHS implementation guide for CYP2C19 genotype testing to guide Clopidogrel use after ...
National Institute for Health and Care Excellence

CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack

NICE has said that CYP2C19 genotype testing can be used to assess whether clopidogrel is a suitable antiplatelet drug for people who have had an ischaemic stroke or a transient ischaemic attack (TIA).